Neoadjuvant chemoimmunotherapy or chemoradiotherapy in stage III non-small cell lung cancer: crossing the Rubicon?
While CT/RT remains essential for certain subsets, particularly T4 or unresectable tumors, CT-IO should be strongly considered for most patients with stage IIIA and IIIB NSCLC.
Authors
- Emilio Fonseca‐Sánchez (ORCID: https://orcid.org/0000-0001-7363-6454)
- E. del Barco (ORCID: https://orcid.org/0000-0001-6443-0585)
- Luis Posado-Domínguez (ORCID: https://orcid.org/0009-0005-4606-2316)
- José Pablo Miramontes‐González (ORCID: https://orcid.org/0000-0002-2247-9679)
- Alejandro Olivares-Hernández (ORCID: https://orcid.org/0000-0003-1992-6105)
- Laura Corvo-Félix
- Juan Carlos Redondo-González (ORCID: https://orcid.org/0009-0001-7368-2263)
Institutions
- Hospital Universitario Río Hortega (ES)
Publication Details
- Journal
- Chinese Clinical Oncology
- Published
- 2025-10-01
- DOI
- https://doi.org/10.21037/cco-25-50
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00